What are the metabolic pathways of erlotinib? What cancers does it work for?

Erlotinib is mainly metabolized by the liver, and its metabolic pathway mainly depends on the cytochrome P450 enzyme system, especially the CYP3A4 enzyme. In addition, CYP1A2 and CYP1A1 are also involved in the metabolism of erlotinib to a certain extent. After oxidative metabolism, the drug is further excreted through bile and feces, with only a small amount excreted in urine. Therefore, patients with abnormal liver function may need to adjust the dose of erlotinib to prevent drug accumulation and toxicity.

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), suitable for patients with non-small cell lung cancer (NSCLC) carrying EGFR sensitive mutations. It can be used for patients with locally advanced or metastatic NSCLC who have progressed after receiving at least one chemotherapy regimen. It can also be used as a first-line treatment for EGFR mutation-positive advanced NSCLC. Erlotinib can block the growth and proliferation of tumor cells by inhibiting the EGFR signaling pathway, thereby delaying disease progression.

In addition to lung cancer, erlotinib is also approved for the treatment of locally advanced, unresectable or metastatic pancreatic cancer. Often, it is used in combination with gemcitabine to increase the effectiveness of the treatment. Studies have shown that although the efficacy of erlotinib in pancreatic cancer is relatively limited, it can prolong the survival of patients to a certain extent, especially for patients with high EGFR expression levels.

Since erlotinib mainly relies on CYP3A4 metabolism, you should avoid taking it with strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) at the same time to avoid affecting drug concentration. In addition, smoking can induce CYP1A2 activity and accelerate the metabolism of erlotinib, thus reducing its plasma concentration. Therefore, patients are advised to quit smoking during treatment to ensure efficacy.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib